MGMT and glioblastoma: First, it remains unclear how the functional output of the Bcl-2:beclin-1 checkpoint varies across GBM molecular contexts (e.g., IDH status, MGMT methylation, and mesenchymal vs. proneural states) and during treatment-induced evolution.